Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection

Current Opinion in Infectious Diseases

Volumn 13, Issue 1, 2000, Pages 19-25

  Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; CARBAMAZEPINE; CD4 IMMUNOGLOBULIN; CHOLESTEROL; CORTICOSTEROID; CYTOCHROME P450 3A4; DIDANOSINE; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; INDINAVIR; INSULIN; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PHENYTOIN; PROTEINASE INHIBITOR; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

CELL COUNT; CENTRAL NERVOUS SYSTEM DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG MIXTURE; DRUG TOLERANCE; FOOD DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; LIVER DISEASE; METABOLIC DISORDER; NONHUMAN; RASH; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 0034028844     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200002000-00004     Document Type: Review

References (22)

1. 1 Gazzard BG, Moyle GJ, on behalf of the BHIVA guidelines writing Committee. 1998 revision to the British HIV Association Guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352:314-316.
2. 2 Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. JAMA 1998; 280:78-86.
3. 3 Moyle GJ. Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice. Exp Opin Invest Drugs 1997; 6:943-964.
4. 4 Carr A, Samaras K, Burton S, Law M, Freund J, Chisolm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58. Key report describing metabolic and clinical manifestations of fat redistribution syndrome(s) and introduction of the term lipodystrophy into the HIV physician's vocabulary.
5. 5 Moyle G, Gazzard BG. Assessment of risk versus benefit for therapeutic intervention with HIV protease inhibitors. Drug Safety 1999; 4:299-321. Discussion of reasons behind the conservative treatment philosophy prevalent in UK HIV care.
6. th Conference on Retroviruses and Opportunistic Infections, Chicago Jan 31-Feb 5, 1999; abstract LB-16.
7. 7 Staszewski S, Morales-Ramirez JO, Godofsky EW, et al. Longer time-to-treatment failure and durability of response with efavirenz+ZDV+3TC: first analysis of full 1266 patient cohort from study 006.39th ICAAC, San Francisco Sept 26-29, 1999; abstract 507. Results of key study comparing efavirenz triple therapy with indinavir triple therapy.
8. th Conference on Retroviruses and Opportunistic Infections, Jan 31-Feb 4 1999; abstract 20.
9. th ICAAC, San Francisco Sept 26-29, 1999; abstract 1-505. Results of key study comparing abacavir triple therapy with indinavir triple therapy.
10. th ICAAC, San Francisco Sept 26-29, 1999; abstract LB-22. Results of key study comparing nevirapine triple therapy with indinavir triple therapy.
11. th Conference on Retroviruses and Opportunistic Infections, Chicago Jan 31-Feb 5, 1999; abstract 18.
12. 12 Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:743-739. Study which established PI therapy as the standard of care.
13. th ICAAC, Toronto Sept 28-Oct 1, 1997: abstract 1-115. Evidence that polymorphisms do not influence treatment response to efavirenz regimens.
14. th World AIDS Conference, Geneva, June 28-July3, 1998: abstract 12203. Results of key study comparing efavirenz triple therapy with nelfinavir triple therapyin treatment experienced patients.
15. 15 Moyle GJ. Efavirenz: shifting the HAART paradigm in adult HIV-1 infection. Exp Opin Invest Drugs 1999; 8:473-486
16. 16 Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996; 5:1183-1199.
17. 17 Walensky RP, Golberg J, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS 1999; 13:999-1000.
18. 18 Moyle G. Triple nucleoside analogue antiretroviral therapy: expanding the treatment approaches for management of HIV infection. Exp Opin Invest Drugs 1999; 8:1147-1155.
19. th ICAAC, San Francisco Sept 26-29, 1999; abstract LB-15. Data on control of lymph node viral activity during efavirenz based therapy.
20. 20 Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine in HIV-infected patients. The INCAS trial. JAMA 1998; 279:930-937. Results of key study which established activity of nevirapine in initial regimens.
21. th World AIDS Conference, Geneva, June 28-July 3, 1998: abstract 22334.
22. th Conference on Retroviruses and Opportunistic Infections, Chicago Jan 31-Feb 5, 1999; abstract 19.